Loading data for CLYM — first visit, this takes a few seconds.

アラート

Climb Bio Inc. (CLYM)

NasdaqGM: CLYM · リアルタイム株価 · USD

17.39

-0.05 (-0.29%)

終値時点： Aug 21, 2026, 2:11 PM

株価、主要な数字、最新ニュースをひとまとめにしたページです。

-0.29% (1D)

データがありません

買気配	9.05
時価総額	1.01B
売上高（TTM）	n/a
純利益（TTM）	-57.62M
	0.08
	-0.8
	n/a
	-16.64
PBR（TTM）	4.21
PSR（TTM）	n/a
決算発表日	Aug 14, 2025

売気配	16.06
出来高	980,703
平均出来高（20日）	1,309,325
始値	16.90
前日終値	17.44
当日レンジ	16.46 - 17.53
52週レンジ	1.54 - 17.53
アナリスト	n/a
目標株価	n/a
配当	n/a
権利落ち日	n/a

CLYMについて

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; a...

[続きを読む]

業種 Biotechnology

セクター Healthcare

IPO日 Aug 10, 2021

従業員数 28

上場取引所 NasdaqGM

ティッカー CLYM

ウェブサイト https://climbbio.com

企業情報の全文

業績

2025年のClimb Bioの売上高は0で、前年の0からundefined%の増加でした。利益は-59.85Mで、-19.01%の減少でした。

財務諸表

決算サプライズ

Climb BioはAug 6, 2026に四半期決算を発表しました：

売上高は $0 で、予想を下回りました $0, うち NaN% の前年比増加にあたります.
EPSは -0.18 で、予想を上回りました 0.03, うち -38.46% の前年比減少.

次回決算発表

Climb Bio Inc.の決算発表予定日は Aug 14, 2025, 寄り付き前の予定です。
アナリストの売上高予想は ... アップグレード

ニュース

1か月前 · Zacks

Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year?

Here is how Artiva Biotherapeutics, Inc. (ARTV) and Climb Bio, Inc. (CLYM) have performed compared to their sector so far this year.

3か月前 · MarketBeat

Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect

Climb Bio (NASDAQ:CLYM) outlined its clinical development strategy and upcoming data readouts during a fireside chat at H.C. Wainwright’s BioConnect Conference, with management emphasizing two biologi...

3か月前 · MarketBeat

Climb Bio Spotlights Budoprutug CD19 Strategy, Sets Up 2026 Data Readouts in pMN, ITP and SLE

Climb Bio (NASDAQ:CLYM) used an investor R&D spotlight event to outline its strategy around CD19-targeted B-cell depletion and to provide updates on development plans and timelines for its lead candid...

3か月前 · Insider Monkey

Climb Bio (CLYM) Enters Agreement for $110M Private Placement Financing

Climb Bio Inc. (NASDAQ:CLYM) is one of the best performing NASDAQ stocks according to Wall Street analysts. On April 28, Climb Bio entered into a securities purchase agreement for a private placement ...

3か月前 · Insider Monkey

Why Climb Bio (CLYM) is One of the Best Performing Small Cap Stocks So Far in 2026

Climb Bio Inc (NASDAQ:CLYM) is one of the best performing small cap stocks so far in 2026. Oppenheimer lifted the price target on Climb Bio Inc (NASDAQ:CLYM) to $18 from $10 on April 12, maintaining a...

2ページ中1ページ

Climb Bio Inc. (CLYM)